Mizuho Cuts LivaNova (NASDAQ:LIVN) Price Target to $70.00

LivaNova (NASDAQ:LIVN - Free Report) had its price objective lowered by Mizuho from $80.00 to $70.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts have also issued reports about the company. Robert W. Baird increased their price objective on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday. Baird R W upgraded shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Stifel Nicolaus upped their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of LivaNova in a research report on Thursday. Finally, The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Stock Performance

LIVN traded up $0.28 during trading on Thursday, reaching $51.62. 523,332 shares of the company were exchanged, compared to its average volume of 622,489. LivaNova has a 52 week low of $42.75 and a 52 week high of $64.47. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $50.93 and a 200 day moving average of $53.15. The stock has a market cap of $2.80 billion, a P/E ratio of -84.52 and a beta of 1.00.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.66 by $0.15. The business had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. On average, sell-side analysts forecast that LivaNova will post 2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hexagon Capital Partners LLC lifted its stake in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock valued at $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp grew its position in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company's stock worth $37,000 after purchasing an additional 332 shares in the last quarter. Lazard Asset Management LLC purchased a new position in LivaNova during the 1st quarter worth approximately $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova during the 2nd quarter valued at $88,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of LivaNova in the first quarter valued at $94,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.